Abstract:
Coronavirus disease 2019 (Covid‐19) is associated with venous and arterial thrombotic complications, especially among those hospitalized with more severe disease. Disturbances in coagulation indices are commonly observed in severe Covid‐19 including marked elevations of plasma D‐dimer that portend a poor prognosis. Emerging evidence points to the inadequacy of standard thromboprophylaxis. And, in an attempt to prevent thrombotic events and potentially limit microvasculature fibrin deposition, more aggressive thromboprophylaxis anticoagulation regimens are considered, including therapeutic dosing of unfractionated heparin (UFH).1 Heparin induced thrombocytopenia (HIT) is an uncommon but potentially life‐threatening complication of heparin exposure. Autoimmune hematologic phenomena have increasingly been recognized during the course of Covid‐19.2, 3 Accordingly, we evaluated the incidence of HIT among hospitalized patients with Covid‐19 treated with intravenous, therapeutic‐dose heparin.
Institutional Review Board approval was obtained. A retrospective cohort analysis was performed for patients hospitalized at Beth Israel Deaconess Medical Center with Covid‐19 confirmed by PCR between February 1, 2020 to May 7, 2020 and received intravenous UFH for ≥5 days. A cut off of 5 days was selected based on the known natural history of HIT. The HIT antibody testing was ordered by the treating physicians and performed by latex immunoassay for anti‐platelet factor 4/heparin antibodies (HemosIL HIT‐Ab).4 Confirmatory testing performed by serotonin release assay (Versiti, Wisconsin). To account for death as a competing risk, estimation of the cumulative incidence of HIT was calculated by competing risk analyses (stcompet, Stata Corp, TX) along with 95% confidence intervals at 25 days from start of heparin infusion.
Among 439 hospitalized patients with Covid‐19, 88 patients who received at least 5 days of UFH were included in the analyses. The target partial thromboplastin time was above 60 seconds in 84 patients and the remaining four patients the target was above 50 seconds. Median duration of heparin exposure was 11 days (IQR 7‐15 days). The most common indications for therapeutic heparin were Covid‐19 coagulopathy (N = 58), confirmed or presumed venous thromboembolism (N = 15), and atrial fibrillation (N = 15). Among eight patients where there was suspicion for HIT, five patients tested positive for HIT by latex immunoassay (Table S1). The cumulative incidence of positive HIT immunoassay assay was 12% at 25 days (95% CI, 4% to 26%, Figure 1). Direct thrombin inhibitors were administered following HIT diagnosis (argatroban N = 4, bivalirudin N = 1). One patient was identified with thrombotic complications in the setting of HIT, this included evidence of acute cerebrovascular infarct as well as extensive areas of splenic infarction. Three patients developed major hemorrhagic events. Three patients died during hospitalization of progressive respiratory failure, one was discharged, and one remains hospitalized.